- Home
- MEGL vs ADXN Comparison
MEGL vs ADXN Comparison
Compare MEGL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- ADXN
- Stock Information
- Founded
- MEGL 2016
- ADXN 2002
- Country
- MEGL Hong Kong
- ADXN Switzerland
- Employees
- MEGL N/A
- ADXN N/A
- Industry
- MEGL Finance: Consumer Services
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- ADXN Health Care
- Exchange
- MEGL Nasdaq
- ADXN Nasdaq
- Market Cap
- MEGL 6.8M
- ADXN 8.0M
- IPO Year
- MEGL 2022
- ADXN N/A
- Fundamental
- Price
- MEGL $1.43
- ADXN $7.94
- Analyst Decision
- MEGL
- ADXN Strong Buy
- Analyst Count
- MEGL 0
- ADXN 1
- Target Price
- MEGL N/A
- ADXN $30.00
- AVG Volume (30 Days)
- MEGL 139.2K
- ADXN 1.5K
- Earning Date
- MEGL 08-26-2025
- ADXN 09-01-2025
- Dividend Yield
- MEGL N/A
- ADXN N/A
- EPS Growth
- MEGL N/A
- ADXN N/A
- EPS
- MEGL N/A
- ADXN 0.10
- Revenue
- MEGL $1,645,862.00
- ADXN $278,508.00
- Revenue This Year
- MEGL N/A
- ADXN $86.57
- Revenue Next Year
- MEGL N/A
- ADXN N/A
- P/E Ratio
- MEGL N/A
- ADXN $0.67
- Revenue Growth
- MEGL N/A
- ADXN N/A
- 52 Week Low
- MEGL $1.02
- ADXN $6.51
- 52 Week High
- MEGL $5.52
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- MEGL 46.93
- ADXN 45.33
- Support Level
- MEGL $1.32
- ADXN $7.52
- Resistance Level
- MEGL $1.50
- ADXN $8.21
- Average True Range (ATR)
- MEGL 0.09
- ADXN 0.10
- MACD
- MEGL 0.00
- ADXN -0.03
- Stochastic Oscillator
- MEGL 26.89
- ADXN 50.00
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.